GUTS Should I Buy

Not a good buy right now for a beginner long-term investor. Despite bullish analyst targets ($8) versus the current ~$1.88, the stock is behaving like a high-volatility biotech with weakening near-term momentum (big regular-session drop and bearish MACD) and no current revenue. With no proprietary buy signals today and no fresh news catalyst this week, the risk/reward is not attractive for an impatient long-term beginner at this exact moment—better to stay on hold rather than buy now.

Price/Trend: Closed at ~$1.881 after a steep -13.68% regular-session move, followed by a modest +2.81% post-market bounce—still signals heavy selling pressure. Momentum: MACD histogram is negative (-0.0159) and negatively expanding, which typically confirms a weakening trend/continued downside momentum. RSI: RSI(6) ~31.9 is near oversold territory, which can support a short-term bounce, but it is not a strong standalone buy signal given the bearish MACD. Moving Averages: Reported as bullish (SMA_5 > SMA_20 > SMA_200), suggesting the broader structure may still be constructive, but the latest sharp drop conflicts with that and indicates near-term trend damage. Levels: Pivot ~2.001 is the key reclaim level; resistance at ~2.227 then ~2.366. Support at ~1.776 then ~1.637. With price below pivot, the technical posture is still defensive. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.